BeiGene

AdvanTIG-301 is an ongoing phase 3, randomized, open-label study to compare tislelizumab plus ociperlimab plus concurrent chemoradiotherapy (cCRT) followed by tislelizumab plus ociperlimab versus cCRT followed by durvalumab in previously untreated, locally advanced, unresectable non-small cell lung cancer (NSCLC).

Chat with BeiGene

Close